Therapeutics: Janus kinase (JAK); JAK-1; JAK-3

Mouse studies suggest JAK inhibitors could help treat spondyloarthritis. In a mouse model of spondyloarthritis, the oral JAK-1/JAK-3 inhibitor Xeljanz tofacitinib citrate decreased inflammation of the synovio-entheseal complex - a hallmark of spondyloarthritis - compared with vehicle. Next steps include testing JAK inhibitors in models of axial spondyloarthritis...